Back to Market Feed

Historical record - last NADAC effective date: 7/16/2018

This NDC is on FDA's drug shortage list (posted Feb 20, 2018)

Product Information

SENSORCAINE 0.5% VIAL is a brand product labeled by Fresenius Kabi USA, LLC, priced at $0.0977 per ML under NDC 63323046757. Its NADAC has been published 239 times since Dec 17, 2014.

FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AP.

SENSORCAINE 0.5% VIAL

BUPIVACAINE HYDROCHLORIDE
$0.0977per ML

Strength

5 mg/mL

NDC

63323046757

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

PERINEURAL

Effective Date

7/16/2018

Active Ingredients

BUPIVACAINE HYDROCHLORIDE

Approval Type

New Drug (NDA)

FDA Application

NDA018304

FDA Approved

Before 1982

TE Code

AP

On Market Since

11/19/2010

Pharmacological Classes

Amide Local Anesthetic
Amides
Local Anesthesia

Price Statistics

The NADAC for SENSORCAINE 0.5% VIAL has been published 239 times since Dec 17, 2014, and over the history we have for it it has risen 17.4%. The table below summarizes its recorded NADAC range and movement.

Current price$0.0977 per ML
All-time high$0.1070 (Jul 11, 2018)
All-time low$0.0832 (Dec 17, 2014)
Median price$0.0892
Average price$0.0906
Largest weekly change+9.5% (Jan 10, 2018)
Weeks tracked239
Tracking sinceDec 17, 2014

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

N/A

3Y

N/A

5Y

N/A

All

+17.4%

Last surveyed Jul 10, 2019 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

1 alternative • Same active ingredient

MARCAINE 0.5% VIAL
Brand
00409161050•Hospira Inc.
$0.0977

Related Drugs

Same classification

SILVADENE 1% CREAM
Brand
61570013140•Pfizer Inc.
$0.1247
per GM
SILVADENE 1% CREAM
Brand
61570013150•Pfizer Inc.
$0.2447
per GM
SILVADENE 1% CREAM
Brand
61570013155•Pfizer Inc.
$0.2447
per GM
XYLOCAINE 2%-EPI 1:100,000
Brand
63323048327•Fresenius Kabi USA, LLC
$0.2655
per ML
XYLOCAINE 1%-EPI 1:100,000
Brand
63323048226•Fresenius Kabi USA, LLC
$0.2721
per ML
XYLOCAINE 1%-EPI 1:100,000
Brand
63323048227•Fresenius Kabi USA, LLC
$0.2721
per ML
SILVADENE 1% CREAM
Brand
61570013185•Pfizer Inc.
$0.2732
per GM
SILVADENE 1% CREAM
Brand
61570013125•Pfizer Inc.
$0.2886
per GM
SILVADENE 1% CREAM
Brand
61570013120•Pfizer Inc.
$0.4328
per GM
CLEOCIN PHOS 600 MG/4 ML VIAL
Brand
00009077526•Pharmacia & Upjohn Company LLC
$0.7024
per ML

Frequently asked questions

What is the NADAC price of SENSORCAINE 0.5% VIAL?

The current National Average Drug Acquisition Cost (NADAC) for SENSORCAINE 0.5% VIAL, manufactured by Fresenius Kabi USA, LLC, is $0.0977 per ML (NDC 63323046757), effective Jul 10, 2019.

How has the price of SENSORCAINE 0.5% VIAL changed over time?

Over the history we have for it, the NADAC for SENSORCAINE 0.5% VIAL has risen 17.4%. It has been tracked across 239 weekly CMS publications since Dec 17, 2014.

What are the highest and lowest recorded NADAC prices for SENSORCAINE 0.5% VIAL?

Since Dec 17, 2014, the NADAC for SENSORCAINE 0.5% VIAL has ranged from a low of $0.0832 (Dec 17, 2014) to a high of $0.1070 (Jul 11, 2018), with a median of $0.0892 per ML.

Are there cheaper alternatives to SENSORCAINE 0.5% VIAL?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SENSORCAINE 0.5% VIAL in a comparable dosage form, but none are currently priced below it.

Who manufactures SENSORCAINE 0.5% VIAL?

SENSORCAINE 0.5% VIAL (NDC 63323046757) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a brand product.

Is SENSORCAINE 0.5% VIAL in shortage?

Yes — NDC 63323046757 is currently listed in FDA's drug shortage database (posted Feb 20, 2018).